Ardelyx Common Stock Net 2013-2024 | ARDX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ardelyx common stock net from 2013 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Ardelyx common stock net from 2013 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.8B
Takeda Pharmaceutical (TAK)	$42.6B
Sandoz Group AG (SDZNY)	$19.5B
Merck (MKKGY)	$19.1B
Astellas Pharma (ALPMY)	$18.3B
United Therapeutics (UTHR)	$16.6B
Summit Therapeutics (SMMT)	$14B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12B
Catalent (CTLT)	$11.1B
Madrigal Pharmaceuticals (MDGL)	$7.6B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$6B
Ionis Pharmaceuticals (IONS)	$5.4B
Crinetics Pharmaceuticals (CRNX)	$5.2B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
NewAmsterdam Pharma (NAMS)	$1.9B
Xencor (XNCR)	$1.8B
Recursion Pharmaceuticals (RXRX)	$1.6B
Evotec AG (EVO)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Harrow (HROW)	$1.5B
Indivior (INDV)	$1.5B
Guardian Pharmacy Services (GRDN)	$1.5B
Ocular Therapeutix (OCUL)	$1.4B